VIVUS to Present at Two Upcoming Investor Conferences
A live audio webcast and 30-day archive of the presentations will beavailable on VIVUS' website at http://www.vivus.com.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetesand sexual health. The company's lead product in clinical development,Qnexa(R), has completed phase 3 clinical trials for the treatment of obesityand an NDA has been filed and accepted by the FDA, with an action date ofOctober 28, 2010. Qnexa is also in phase 2 clinical development for thetreatment of type 2 diabetes and obstructive sleep apnea. In the area ofsexual health, VIVUS is in phase 3 development with avanafil, a potentiallybest-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and inphase 2 development of Luramist(TM) for the treatment of hypoactive sexualdesire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generationtherapy for the treatment of ED, is already on the market and generatingrevenue for VIVUS. For more information about the company, please visitwww.vivus.com.The conference presentation schedule is as follows: Cowen and Company 30th Annual Health Care Conference March 10, 2010 at 9:30 a.m. ET The Boston Marriott Copley Place, Boston, MA Roth Capital Partners 22nd Annual OC Growth Stock Conference March 16, 2010 at 12:00 p.m. PT The Ritz Carlton, Dana Point, CA
SOURCE VIVUS, Inc.
You May Also Like